MAX
Company Analysis Laboratorios Farmaceuticos Rovi, S.A.
1. Summary
Advantages
- Dividends (2.75%) are higher than the sector average (1.69%).
- The stock's return over the last year (0%) is higher than the sector average (-7.99%).
- The company's current efficiency (ROE=25.83%) is higher than the sector average (ROE=14.4%)
Disadvantages
- Price (90.61 $) is higher than fair price (52.06 $)
- Current debt level 13.75% has increased over 5 years from 12.8%.
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Laboratorios Farmaceuticos Rovi, S.A. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | -22.6% | -0.8% |
| 90 days | 0% | -17.4% | 3.6% |
| 1 year | 0% | -8% | 12.3% |
LABFF vs Sector: Laboratorios Farmaceuticos Rovi, S.A. has outperformed the "Healthcare" sector by 7.99% over the past year.
LABFF vs Market: Laboratorios Farmaceuticos Rovi, S.A. has significantly underperformed the market by -12.34% over the past year.
Stable price: LABFF is not significantly more volatile than the rest of the market on "OTC" over the last 3 months, with typical variations of +/- 5% per week.
Long period: LABFF with weekly volatility of 0% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (90.61 $) is higher than the fair price (52.06 $).
Price is higher than fair: The current price (90.61 $) is 42.5% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (32.61) is lower than that of the sector as a whole (41.11).
P/E vs Market: The company's P/E (32.61) is lower than that of the market as a whole (47.24).
5.2.1 P/E Similar companies
5.3. P/BV
P/BV vs Sector: The company's P/BV (7.68) is higher than that of the sector as a whole (3.58).
P/BV vs Market: The company's P/BV (7.68) is higher than that of the market as a whole (4.27).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (5.84) is higher than that of the sector as a whole (3.9).
P/S vs Market: The company's P/S indicator (5.84) is lower than that of the market as a whole (12.17).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (21.91) is higher than that of the sector as a whole (15.97).
EV/Ebitda vs Market: The company's EV/Ebitda (21.91) is lower than that of the market as a whole (24.87).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Rising and has grown by 1.9% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (1.9%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-45.01%).
6.4. ROE
ROE vs Sector: The company's ROE (25.83%) is higher than that of the sector as a whole (14.4%).
ROE vs Market: The company's ROE (25.83%) is lower than that of the market as a whole (50.34%).
6.6. ROA
ROA vs Sector: The company's ROA (17.6%) is higher than that of the sector as a whole (7.44%).
ROA vs Market: The company's ROA (17.6%) is lower than that of the market as a whole (35.27%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (14.06%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (10.86%).
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
8. Dividends
8.1. Dividend yield vs Market
High yield: The dividend yield of the company 2.75% is higher than the average for the sector '1.69%.
8.2. Stability and increase in payments
Dividend stability: The company's dividend yield 2.75% has been steadily paid over the past 7 years, DSI=0.83.
Weak dividend growth: The company's dividend yield 2.75% has been growing weakly or stagnant over the past 5 years. Growth over only 2 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (41.24%) are at a comfortable level.
Based on sources: porti.ru
